Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (enero de 2001). «The hormone resistin links obesity to diabetes». Nature409 (6818): 307-12. PMID11201732. doi:10.1038/35053000.
Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV (noviembre de 2003). «Serum resistin (FIZZ3) protein is increased in obese humans». J. Clin. Endocrinol. Metab.88 (11): 5452-5. PMID14602788. doi:10.1210/jc.2002-021808.
Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N (octubre de 2002). «Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?». Diabetes51 (10): 2951-8. PMID12351432. doi:10.2337/diabetes.51.10.2951.
Levy JR, Davenport B, Clore JN, Stevens W (marzo de 2002). «Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats». Am. J. Physiol. Endocrinol. Metab.282 (3): E626-33. PMID11832366. doi:10.1152/ajpendo.00346.2001.
McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S (enero de 2002). «Resistin, central obesity, and type 2 diabetes». Lancet359 (9300): 46-7. PMID11809189. doi:10.1016/S0140-6736(02)07281-1.
Adeghate E (octubre de 2004). «An update on the biology and physiology of resistin». Cell. Mol. Life Sci.61 (19-20): 2485-96. PMID15526156. doi:10.1007/s00018-004-4083-2.
Stumvoll M, Häring H (noviembre de 2002). «Resistin and adiponectin--of mice and men». Obes. Res.10 (11): 1197-9. PMID12429885. doi:10.1038/oby.2002.162.
Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C (junio de 2004). «Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity». Obes. Res.12 (6): 962-71. PMID15229336. doi:10.1038/oby.2004.118.
Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, Kumar S, McTernan PG (enero de 2007). «The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes». J. Clin. Endocrinol. Metab.92 (1): 270-6. PMID17062773. doi:10.1210/jc.2006-1151.
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (diciembre de 2006). «Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients». Transplant. Proc.38 (10): 3434-6. PMID17175295. doi:10.1016/j.transproceed.2006.10.140.
Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, Vettor R (noviembre de 2002). «Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss». Obes. Res.10 (11): 1095-103. PMID12429872. doi:10.1038/oby.2002.149.
Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ (septiembre de 2005). «Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway». Biochem. Biophys. Res. Commun.334 (4): 1092-101. PMID16039994. doi:10.1016/j.bbrc.2005.06.202.
Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA (agosto de 2003). «Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction». Circulation108 (6): 736-40. PMID12874180. doi:10.1161/01.CIR.0000084503.91330.49.
Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (abril de 2004). «Adiponectin differentially regulates cytokines in porcine macrophages». Biochem. Biophys. Res. Commun.316 (3): 924-9. PMID15033490. doi:10.1016/j.bbrc.2004.02.130.
Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Bárány P, Lönnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (febrero de 2006). «Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance». Kidney Int.69 (3): 596-604. PMID16395259. doi:10.1038/sj.ki.5000089.
Asensio C, Cettour-Rose P, Theander-Carrillo C, Rohner-Jeanrenaud F, Muzzin P (mayo de 2004). «Changes in glycemia by leptin administration or high- fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis». Endocrinology145 (5): 2206-13. PMID14962997. doi:10.1210/en.2003-1679.
Lee JH, Bullen JW, Stoyneva VL, Mantzoros CS (marzo de 2005). «Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia». Am. J. Physiol. Endocrinol. Metab.288 (3): E625-32. PMID15522996. doi:10.1152/ajpendo.00184.2004.
Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S (abril de 2004). «Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines». Metab. Clin. Exp.53 (4): 430-4. PMID15045687. doi:10.1016/j.metabol.2003.11.022.
McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S (mayo de 2002). «Increased resistin gene and protein expression in human abdominal adipose tissue». J. Clin. Endocrinol. Metab.87 (5): 2407. PMID11994397. doi:10.1210/jc.87.5.2407.
Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS (julio de 2004). «Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting». Diabetes53 (7): 1671-9. PMID15220189. doi:10.2337/diabetes.53.7.1671.
Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ (octubre de 2003). «Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance». Eur. J. Endocrinol.149 (4): 331-5. PMID14514348. doi:10.1530/eje.0.1490331.
Smith SR, Bai F, Charbonneau C, Janderová L, Argyropoulos G (julio de 2003). «A promoter genotype and oxidative stress potentially link resistin to human insulin resistance». Diabetes52 (7): 1611-8. PMID12829623. doi:10.2337/diabetes.52.7.1611.
Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M (enero de 2004). «Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes». Clin. Chim. Acta339 (1-2): 57-63. PMID14687894. doi:10.1016/j.cccn.2003.09.009.
McTernan PG, Fisher FM, Valsamakis G, et al. (diciembre de 2003). «Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes». J. Clin. Endocrinol. Metab.88 (12): 6098-106. PMID14671216. doi:10.1210/jc.2003-030898.
Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M (enero de 2003). «Resistin release by human adipose tissue explants in primary culture». Biochem. Biophys. Res. Commun.300 (3): 674-8. PMID12507502. doi:10.1016/S0006-291X(02)02864-4.
Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (octubre de 2003). «Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects». J. Clin. Endocrinol. Metab.88 (10): 4848-56. PMID14557464. doi:10.1210/jc.2003-030519.
Nagaev I, Smith U (julio de 2001). «Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle». Biochem. Biophys. Res. Commun.285 (2): 561-4. PMID11444881. doi:10.1006/bbrc.2001.5173.
Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR' (abril de 2004). «Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects». J. Clin. Endocrinol. Metab.89 (4): 1844-8. PMID15070954. doi:10.1210/jc.2003-031410.
Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S (octubre de 2001). «Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans». Diabetes50 (10): 2199-202. PMID11574398. doi:10.2337/diabetes.50.10.2199.
Way JM, Görgün CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS (julio de 2001). «Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists». J. Biol. Chem.276 (28): 25651-3. PMID11373275. doi:10.1074/jbc.C100189200.
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (enero de 2001). «The hormone resistin links obesity to diabetes». Nature409 (6818): 307-12. PMID11201732. doi:10.1038/35053000.
Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV (noviembre de 2003). «Serum resistin (FIZZ3) protein is increased in obese humans». J. Clin. Endocrinol. Metab.88 (11): 5452-5. PMID14602788. doi:10.1210/jc.2002-021808.
Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N (octubre de 2002). «Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?». Diabetes51 (10): 2951-8. PMID12351432. doi:10.2337/diabetes.51.10.2951.
Levy JR, Davenport B, Clore JN, Stevens W (marzo de 2002). «Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats». Am. J. Physiol. Endocrinol. Metab.282 (3): E626-33. PMID11832366. doi:10.1152/ajpendo.00346.2001.
McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S (enero de 2002). «Resistin, central obesity, and type 2 diabetes». Lancet359 (9300): 46-7. PMID11809189. doi:10.1016/S0140-6736(02)07281-1.
Adeghate E (octubre de 2004). «An update on the biology and physiology of resistin». Cell. Mol. Life Sci.61 (19-20): 2485-96. PMID15526156. doi:10.1007/s00018-004-4083-2.
Stumvoll M, Häring H (noviembre de 2002). «Resistin and adiponectin--of mice and men». Obes. Res.10 (11): 1197-9. PMID12429885. doi:10.1038/oby.2002.162.
Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, Simón I, Soler J, Richart C (junio de 2004). «Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity». Obes. Res.12 (6): 962-71. PMID15229336. doi:10.1038/oby.2004.118.
Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, Kumar S, McTernan PG (enero de 2007). «The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes». J. Clin. Endocrinol. Metab.92 (1): 270-6. PMID17062773. doi:10.1210/jc.2006-1151.
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (diciembre de 2006). «Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients». Transplant. Proc.38 (10): 3434-6. PMID17175295. doi:10.1016/j.transproceed.2006.10.140.
Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, Vettor R (noviembre de 2002). «Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss». Obes. Res.10 (11): 1095-103. PMID12429872. doi:10.1038/oby.2002.149.
Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ (septiembre de 2005). «Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway». Biochem. Biophys. Res. Commun.334 (4): 1092-101. PMID16039994. doi:10.1016/j.bbrc.2005.06.202.
Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA (agosto de 2003). «Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction». Circulation108 (6): 736-40. PMID12874180. doi:10.1161/01.CIR.0000084503.91330.49.
Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (abril de 2004). «Adiponectin differentially regulates cytokines in porcine macrophages». Biochem. Biophys. Res. Commun.316 (3): 924-9. PMID15033490. doi:10.1016/j.bbrc.2004.02.130.
Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Bárány P, Lönnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (febrero de 2006). «Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance». Kidney Int.69 (3): 596-604. PMID16395259. doi:10.1038/sj.ki.5000089.
Asensio C, Cettour-Rose P, Theander-Carrillo C, Rohner-Jeanrenaud F, Muzzin P (mayo de 2004). «Changes in glycemia by leptin administration or high- fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis». Endocrinology145 (5): 2206-13. PMID14962997. doi:10.1210/en.2003-1679.
Lee JH, Bullen JW, Stoyneva VL, Mantzoros CS (marzo de 2005). «Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia». Am. J. Physiol. Endocrinol. Metab.288 (3): E625-32. PMID15522996. doi:10.1152/ajpendo.00184.2004.
Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S (abril de 2004). «Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines». Metab. Clin. Exp.53 (4): 430-4. PMID15045687. doi:10.1016/j.metabol.2003.11.022.
McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S (mayo de 2002). «Increased resistin gene and protein expression in human abdominal adipose tissue». J. Clin. Endocrinol. Metab.87 (5): 2407. PMID11994397. doi:10.1210/jc.87.5.2407.
Duman BS, Turkoglu C, Gunay D, Cagatay P, Demiroglu C, Buyukdevrim AS (agosto de 2003). «The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: evidence supporting central obesity». Diabetes Nutr. Metab.16 (4): 243-50. PMID14768774.
Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS (julio de 2004). «Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting». Diabetes53 (7): 1671-9. PMID15220189. doi:10.2337/diabetes.53.7.1671.
Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ (octubre de 2003). «Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance». Eur. J. Endocrinol.149 (4): 331-5. PMID14514348. doi:10.1530/eje.0.1490331.
Smith SR, Bai F, Charbonneau C, Janderová L, Argyropoulos G (julio de 2003). «A promoter genotype and oxidative stress potentially link resistin to human insulin resistance». Diabetes52 (7): 1611-8. PMID12829623. doi:10.2337/diabetes.52.7.1611.
Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M (enero de 2004). «Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes». Clin. Chim. Acta339 (1-2): 57-63. PMID14687894. doi:10.1016/j.cccn.2003.09.009.
McTernan PG, Fisher FM, Valsamakis G, et al. (diciembre de 2003). «Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes». J. Clin. Endocrinol. Metab.88 (12): 6098-106. PMID14671216. doi:10.1210/jc.2003-030898.
Tjokroprawiro A (2006). «New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer)». Acta Med Indones38 (3): 160-6. PMID17119268.
Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M (enero de 2003). «Resistin release by human adipose tissue explants in primary culture». Biochem. Biophys. Res. Commun.300 (3): 674-8. PMID12507502. doi:10.1016/S0006-291X(02)02864-4.
Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (octubre de 2003). «Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects». J. Clin. Endocrinol. Metab.88 (10): 4848-56. PMID14557464. doi:10.1210/jc.2003-030519.
Nagaev I, Smith U (julio de 2001). «Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle». Biochem. Biophys. Res. Commun.285 (2): 561-4. PMID11444881. doi:10.1006/bbrc.2001.5173.
Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR' (abril de 2004). «Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects». J. Clin. Endocrinol. Metab.89 (4): 1844-8. PMID15070954. doi:10.1210/jc.2003-031410.
Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S (octubre de 2001). «Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans». Diabetes50 (10): 2199-202. PMID11574398. doi:10.2337/diabetes.50.10.2199.
Way JM, Görgün CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS (julio de 2001). «Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists». J. Biol. Chem.276 (28): 25651-3. PMID11373275. doi:10.1074/jbc.C100189200.